Wakamoto Pharmaceutical Co (TSE:4512) Cyclically Adjusted Revenue per Share: 円305.08 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円294.00
GF Value 円310.31
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Wakamoto Pharmaceutical Co TSE:4512 -0.68% 63 Cyclically Adjusted Revenue per Share is 円305.08 as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円310.31 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Wakamoto Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円-51.456. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円305.08 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Wakamoto Pharmaceutical Co was 0.10% per year. The lowest was -0.40% per year. And the median was -0.30% per year.

As of today (2026-09-10), Wakamoto Pharmaceutical Co's current stock price is 円294.00. Wakamoto Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円305.08. Wakamoto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wakamoto Pharmaceutical Co was 2.14. The lowest was 0.62. And the median was 0.87.


Wakamoto Pharmaceutical Co  (TSE:4512) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Wakamoto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=294.00/305.08
=0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wakamoto Pharmaceutical Co was 2.14. The lowest was 0.62. And the median was 0.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Wakamoto Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Wakamoto Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 304.77 308.32 305.68 0.00 305.08

Wakamoto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 308.46 306.36 321.63 305.08 0.00

TSE:4512 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wakamoto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Wakamoto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wakamoto Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-51.456/112.7000*112.7000
=-51.456

Current CPI (Mar. 2026) = 112.7000.

Wakamoto Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 75.580 97.900 87.006
201606 83.088 98.100 95.454
201609 74.935 98.000 86.175
201612 82.045 98.400 93.968
201703 71.867 98.100 82.563
201706 78.192 98.500 89.464
201709 77.992 98.800 88.965
201712 85.337 99.400 96.755
201803 72.465 99.200 82.327
201806 77.711 99.200 88.287
201809 72.874 99.900 82.211
201812 82.381 99.700 93.123
201903 76.530 99.700 86.509
201906 78.889 99.800 89.086
201909 76.151 100.100 85.736
201912 89.486 100.500 100.349
202003 70.041 100.300 78.700
202006 61.388 99.900 69.254
202009 61.976 99.900 69.917
202012 68.959 99.300 78.265
202103 63.955 99.900 72.149
202106 56.629 99.500 64.142
202109 58.824 100.100 66.228
202112 65.095 100.100 73.289
202203 60.926 101.100 67.917
202206 58.299 101.800 64.541
202209 57.518 103.100 62.874
202212 64.779 104.100 70.131
202303 68.931 104.400 74.411
202306 53.602 105.200 57.423
202309 50.655 106.200 53.755
202312 56.700 106.800 59.832
202403 62.006 107.200 65.187
202406 53.123 108.200 55.332
202409 55.508 108.900 57.445
202503 0.000 111.100 0.000
202506 62.385 111.700 62.944
202509 63.783 112.000 64.182
202512 210.639 113.000 210.080
202603 -51.456 112.700 -51.456

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円305.08 mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Cyclically Adjusted Revenue per Share of 円305.08 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Wakamoto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円305.08. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Wakamoto Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円305.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円305.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円310.31, compared to a current price of 円294.00 — trading 5.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円305.08. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Cyclically Adjusted Revenue per Share is 円305.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円294.00 is trading 5.3% below its estimated GF Value™ of 円310.31. GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4512:

  • Cyclically Adjusted Revenue per Share: 円305.08
  • GF Value™: 円310.31 vs. price of 円294.00 (5.3% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円294.00
Price
円310.31
GF Value